Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GFER | P55789 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.31 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.31 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.31 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.31 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.31 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.31 |
| ▸ | RPS6KA2 | Q15349 | 1/20 | 0.31 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10183041 | 0.95 | KDM4E (0.36) | GFERKDM4EALDH1A1POLBHPGD | |
| SCHEMBL10183113 | 0.89 | KDM4E (0.32) | KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL22102449 | 0.77 | GFER (0.42) | GFERKDM4EALDH1A1POLBHPGD | |
| SCHEMBL23022340 | 0.73 | GFER (0.42) | GFERKDM4EALDH1A1POLBHPGD | |
| SCHEMBL22050615 | 0.72 | GFER (0.39) | GFERKDM4EALDH1A1POLBHPGD | |
| SCHEMBL10183038 | 0.69 | AR (0.44) | KDM4EALDH1A1POLBHPGDHSD17B10 | |
| SCHEMBL21672360 | 0.69 | GFER (0.32) | GFERRPS6KA2 | |
| SCHEMBL10183044 | 0.68 | MAPK1 (0.47) | KDM4EALDH1A1POLBHPGDHSD17B10 | |
| SCHEMBL16370050 | 0.68 | KDM4E (0.40) | GFERKDM4EALDH1A1POLBHPGD | |
| SCHEMBL12376780 | 0.67 | KDM4E (0.41) | KDM4EALDH1A1POLBHPGDMAPK10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200039998-A1 | AMINE-SUBSTITUTED HETEROCYCLIC COMPOUNDS AS EHMT2 INHIBITORS AND METHODS OF USE THEREOF | Epizyme, Inc. | 2020-02-06 | — | — | US | disclosed |
| US-20120040951-A1 | HETEROARYL COMPOUNDS USEFUL AS RAF KINASE INHIBITORS | SUNESIS PHARMACEUTICALS, INC. | 2012-02-16 | — | — | US | disclosed |
| US-20120040951-A1 | HETEROARYL COMPOUNDS USEFUL AS RAF KINASE INHIBITORS | SUNESIS PHARMACEUTICALS, INC. | 2012-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040951-A1 | HETEROARYL COMPOUNDS USEFUL AS RAF KINASE INHIBITORS | BRAF, RAF1, ARAF | GFER 2556/4885KDM4E 2722/4885ALDH1A1 1934/4885 |
| US-20200039998-A1 | AMINE-SUBSTITUTED HETEROCYCLIC COMPOUNDS AS EHMT2 INHIBITORS AND METHODS OF USE THEREOF | HNMT, BHMT, EHMT2 | GFER 1636/4885KDM4E 222/4885ALDH1A1 180/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.